Frank has spent over twenty years in biopharmaceuticals serving in commercial leadership roles. At Takeda, Amylin, and Acadia Pharmaceuticals he was a founding member of the team that brought them from R&D-only into launch-ready commercial organizations. His 15 product launches include large market brands such as Lipitor to orphan drug portfolios. 

Frank’s strong record of increasing company value has resulted in company acquisitions of over $100 billion.